Much of the focus of the preeclampsia research field span across these four categories: “prediction”, “prevention”, “treatments”, and “outcomes” from preeclampsia (short- and long-term morbidity and mortality). The highest risk/reward research, but arguably the most difficult, is in the prevention and treatment categories. Right now, low-dose aspirin is the most common medication consistently recommended to lower risk for preeclampsia. There is a lack of any other medications/therapeutics on the market approved to prevent or cure preeclampsia once it develops. (It is important to note that magnesium sulfate is highly effective and approved for preventing and treating eclamptic seizures. It does not, however, halt the progression of the high blood pressure which characterizes preeclamspia.)
Research is being done to make a medicine that can cure preeclampsia a reality. In this article, researchers asked: what are the candidate medicines being studied currently to prevent or treatment preeclampsia? After an extensive review of the literature and clinical trial databases, researchers of this article identified 87 candidate medicines in clinical development. Within that list, researchers classified 7 as “high potential” and 8 as “medium potential”. Some of the candidate medicines for preventing preeclampsia listed include: esomeprazole, L-arginine, vitamin D, metformin, probiotic lactobacilli, selenium. Some of the candidate medicines listed for treatment of preeclampsia included: sulfasalazine, metformin, pravastatin, and omega-3 fatty acid.
Take home message: Research that puts together all of the current research in one place is helpful to set the direction for new studies and research funding. Gathering information on all the potential preeclampsia treatments or preventions in one article, to report and evaluate what has been done so far, helps move the research & development field for preeclampsia medicines forward.
Link: https://rdcu.be/cYYyS
Citation: McDougall ARA, Hastie R, Goldstein M, Tuttle A, Tong S, Ammerdorffer A, Gülmezoglu AM, Vogel JP. Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles. BMC Med. 2022 Nov 4;20(1):393. doi: 10.1186/s12916-022-02582-z. PMID: 36329468; PMCID: PMC9635102.
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...
Current Status and Prospects of the Single-Cell Sequencing Technologies for Revealing the Pathogenesis of Pregnancy-Associated Disorders The adult human body is made up of about 100 trillion cells. I...
First-Trimester Screening for HELLP Syndrome—Prediction Model Based on MicroRNA Biomarkers and Maternal Clinical Characteristics Hypertensive disorders of pregnancy and cardiovascular disease a...